Biosig Technologies Inc represents values of innovation, quality, and integrity. The company is dedicated to developing and commercializing advanced biomedical signal processing platforms. Biosig Technologies Inc focuses on improving patient outcomes and providing cutting-edge solutions to the medical field. With a commitment to excellence, the company invests in research and development to develop innovative medical technologies. Biosig Technologies Inc's corporate philosophy emphasizes collaboration, transparency, and ethical practices in all its operations. The company's dedication to improving healthcare and delivering value to stakeholders is reflected in its continual advancements and contributions to the industry.

Biosig Technologies Inc is primarily present in the United States.

Biosig Technologies Inc has achieved significant milestones in its industry. Some notable achievements include the development and commercialization of its proprietary medical device, the PURE EP System. The company has also made significant progress in securing regulatory clearances, such as the FDA approval for the PURE EP System in 2018. Biosig Technologies Inc continues to advance its research and development efforts, fostering innovation and expanding its presence in the healthcare sector. With a strong commitment to improving patient care and outcomes, Biosig Technologies Inc is dedicated to revolutionizing electrophysiology and making a positive impact in the medical field.

Biosig Technologies Inc, a leading medical technology company, was founded in 2009. The company specializes in developing innovative biomedical signal processing solutions. With a focus on improving patient outcomes, Biosig Technologies has developed an advanced signal processing platform called the Pure EP System. This cutting-edge system is designed to enhance the accuracy and effectiveness of electrophysiology procedures, particularly for cardiac arrhythmia treatments. Through extensive research and development, Biosig Technologies is dedicated to providing healthcare professionals with state-of-the-art tools for precise diagnosis and treatment planning. As a result, Biosig Technologies Inc has gained a strong reputation as a trusted provider of advanced medical technologies in the market.

The main competitors of Biosig Technologies Inc in the market include Abiomed Inc, Medtronic plc, Boston Scientific Corporation, and Edwards Lifesciences Corporation.

Biosig Technologies Inc is primarily active in the healthcare and medical device industry.

The business model of Biosig Technologies Inc revolves around the development and commercialization of innovative biomedical devices. The company focuses on the design, manufacturing, and distribution of advanced signal processing platforms for the healthcare industry. Biosig Technologies specializes in developing products that enhance the analysis and monitoring of physiological signals for improved disease diagnosis and therapy. With a strong emphasis on research and development, as well as strategic partnerships, Biosig Technologies aims to provide cutting-edge solutions that address critical medical needs and contribute to the advancement of patient care.

BioSig Technologies의 P/E 비율은 -0.57입니다.

BioSig Technologies의 P/S 비율은 0입니다.

BioSig Technologies에 대한 AlleAktien 품질 점수는 5/10입니다.

BioSig Technologies에 대한 현재 매출은 계산할 수 없습니다.

예상되는 BioSig Technologies 이익은 -14.4 백만 USD입니다.

Biosig Technologies Inc. is a rising company that focuses on the development of medical devices and systems for cardiovascular diseases and neurological disorders. It was founded in 1998 and is headquartered in Westport, Connecticut. The company's core business revolves around researching, developing, manufacturing, and marketing medical devices and systems for the diagnosis and treatment of cardiovascular diseases and neurological disorders. They are a leading provider of innovative solutions that improve accuracy and effectiveness in patient diagnosis and treatment. Their main areas of expertise are electrophysiological systems for cardiovascular applications and technology platforms for neurological applications. They emphasize partnerships with other companies and research institutions to develop innovative solutions. Their current products include the PURE EP System for diagnosing and treating complex cardiac arrhythmias, and the NeurECG System for recording and analyzing electrophysiological signals from the brain for diagnosing and treating neurological disorders. In summary, Biosig Technologies specializes in developing and marketing medical devices and systems, and has established itself as a leading provider in the field of cardiovascular and neurological diagnostics and treatments through their innovative products and collaboration with other industry and research partners.

BioSig Technologies은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

BioSig Technologies의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

BioSig Technologies의 ISIN은 US09073N2018입니다.

BioSig Technologies의 WKN은 A2N5TW입니다.

BioSig Technologies의 티커는 BSGM입니다.

지난 12개월 동안 BioSig Technologies은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 BioSig Technologies은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

BioSig Technologies의 현재 배당 수익률은 입니다.

BioSig Technologies은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

BioSig Technologies은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

BioSig Technologies은 '건강' 섹터에 속합니다.

BioSig Technologies의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 BioSig Technologies는 0 USD를 배당금으로 지급했습니다.

BioSig Technologies의 배당금은 USD에 지급됩니다.